Breast Cancer Research and Treatment **54**: 279, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 54

Acito L 165
Alfarano A 101
Amichetti M 109
Angiona S 165
Apolone G 47
Arcicasa M 109
Armaroli L 109
Asselain B 83
Auerma K 261
Avanzato G 235

Bardou VJ 205
Becchis M 101
Berger U 147
Bertucci F 205
Biglia N 101
Bilancia D 165
Birbaum D 205
Brentani MM 123
Broët P 83
Bryant JE 57
Bull AA 47
Buzdar A 225

Caffo O 109
Camerlo J 205
Carella C 235
Castellsague X 39
Castilla JA 159
Coghetto F 109
Colton T 25
Coluccia C 101
Compas BE 195
Cristofanilli M 225

Danmayr E 255
de la Rochefordière A 83
De Rycke Y 83
Degner LF 185
Di Costanzo F 165
Drudis T 39

Eliza M 245
Epping-Jordan JE 195
Escaleira MTF 123
Escobedo A 39
Esparza L 225
Ethier SP 173

Fabra A 39
Fazzari A 101
Ferrera P 101
Field T 25
Fioriti L 165
Fordyce CA 57
Fortunati N 101
Fourquet A 83
Frairia R 101
Frank W 255
Frank W 65
Friedl HP 255
Fung J 73

Gasperoni S 165
Gazit G 135
Gilliland FD 57
Giustini L 165
Graeff H 147
Gravis G 205
Griffith JK 57
Gutierrez LS 245

Hack TF 185
Hakama H 261
Harbeck N 147
Hart S 47
Hartmann LC 117
Hassoun J 205
Heinonen O-P 261
Hellmén E 11
Herruzo A 159
Höfler H 147
Holmes FA 225
Hortobagyi GN 225
Houvenaeghel G 205

Ignatoski KMW 173
Ingle JN 117

Jacquemier J 205
Jänicke F 147
Joste NE 57

Kalish SC 25
Kan L 73
Kates RE 147
Krag DN 195
Kwant MM 11

Lanari C 93
Lee AS 135
Leivo T 261
Leodolter S 65,255
Liberati A 47
Lippman ME 1
Loprinzi CL 117
Lora O 109
Lu J 135
Luparello C 235

Manzione L 165
Maraninchi D 205
Marcos C 159
Mates D 73
McLachlan S-A 213
Medl M 65,255
Menjón S 159
Meyerowitz BE 47
Mol JA 11
Molinolo A 93
Montechia MF 93
Mor G 245
Moreno A 39
Mosconi P 47
Mosseri V 83
Moyzis RK 57

Naftolin F 245
Neidhart JA 225
Neri S 109

Olivotto IA 73
Ondei S 101
Oosterlaken-Dijksterhuis MA 11
Oppedisano G 195
Oziel-Taïeb S 205

Partanen K 261
Peethambaram PP 117
Penault-Llorca F 205
Peters-Engl C 65,255
Pintilie M 213
Pouillart P 83
Prout MN 25
Pucci-Minafra I 235
Puig B 205

Ramachandran C 269
Ramírez A 159
Resbeut M 205
Rigon A 109
Roncadin M 109

Saari U 261
Salminen T 261
Samant R 73
Schmitt M 147
Schmoor C 31
Scholl SM 83
Schumacher M 31
Sdrobolini A 165
Sierra A 39
Silliman RA 25
Sintonen H 261
Sismondi P 101
Slob A 11
Stoll MF 195
Suman VJ 117

Tannock IF 213
Teodorani N 109
Thomsen AH 195
Thomssen C 147
Tuominen R 261

Ulm K 147

Valenti L 165
Valero V 225
Viens P 205

Warren Burhenne LJ 73

Yang X 1
You W 269

Zini G 109
Zorat P 109

Breast Cancer Research and Treatment **54**: 281-284, 1999.
© 1999 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 54

adjuvant therapy
  angiogenesis, low PgR, and poor survival in node-positive breast cancer with adjuvant anthracycline 205-212
advanced breast cancer
  phase II trial of mitoxantrone doses with fixed paclitaxel 165-171
  quality of life and cost issues in third-line chemotherapy 213-223
age factors
  differences in coping, psychological adjustment to breast cancer 195-203
anchorage-independent growth
  association with constitutive activation of FAK 173-182
aneuploidy
  correlation with reduced telomere DNA content 59-64
angiogenesis
  and poor survival in node-positive breast cancer with anthracycline adjuvant therapy 205-212
apoptosis
  and curcumin effects in breast cancer vs. normal mammary epithelial cell lines 269-278
  blocking by synergistic c-Myc and Bcl-2, in lymph node metastasis 39-45
  of activated lymphocytes induced by Fas-ligand from tumor cells 245-253

Bcl-2
  synergizes with c-Myc in promoting lymph node metastasis 39-45
benign breast disease
  lower breast cyst fluid TNFα, IL-6, but not IL-1, in high risk group (K+/Na+ > 3) 159-164
blood flow
  measured in tumors by ultrasound as a prognostic factor 65-71
BRCA1 and BRCA2
  review of mutations and roles 1-10
breast conservation
  with radiation therapy in DCIS — quality of life 109-115

canine mammary tumor cell line CMT-U335
  regulation of IGFBP's by IGF-I and retinoic acid 11-23
cardiopulmonary comorbidity
  and decline of upper body function after breast cancer treatments 25-30
cathepsin D
  low prognostic significance vs. PAI-1, uPA, SPF 147-157
chemoprevention
  effects of curcumin in normal epithelial vs. breast cancer cell lines 269-278
chemotherapy
  high-dose — argument for randomized trials 31-38
  phase I/II trial of high-dose mitoxantrone — no advantage over standard dose 225-233
  phase II trial of mitoxantrone doses with fixed paclitaxel 165-171
  third-line — quality of life and cost issues 213-223
cluster analysis
  decisional control, psychological adjustment, and frustration expression in breast cancer patients 185-194
cognitive avoidance
  and poor psychological adjustment to breast cancer 185-194
collagenase inhibitors
  TIMP-1 is also an autocrine/paracrine growth factor 235-244
conservative surgery
  with radiation therapy in DCIS — quality of life 109-115
coping modes
  age-related differences and emotional distress in breast cancer 195-203
  in cluster analysis of psychological adjustment to breast cancer 185-194
cost-effectiveness
  and quality of life in deciding on third-line chemotherapy 213-223
  of double-reading of mammograms in screening 261-267
curcumin
  apoptotic effects in breast cancer vs. normal epithelial cell lines 269-278
cyst fluid
  lower TNFα, IL-6, but not IL-1, in high risk group (K+/Na+ > 3) 159-164

decisional control
in cluster analysis of psychological adjustment to breast cancer 185-194
diethylstilbestrol (DES)
randomized trial vs. tamoxifen in metastatic breast cancer 117-122
DNA repair
review of BRCA1 and BRCA2 roles 1-10
Doppler ultrasound
measuring tumor blood flow as a prognostic factor 65-71
ductal carcinoma in situ (DCIS)
quality of life after conservative surgery with radiation 109-115

emotional distress
age-related differences in coping behavior and adjustment to breast cancer 195-203
endocrine therapy
ER, PgR, and reversibility of estrogen resistance in mouse model 93-99
randomized trial of DES vs. tamoxifen in metastatic breast cancer 117-122
endometrial cancer
non-significant increased risk with tamoxifen (4109 patients) 255-260
erbB-2 (HER-2/*neu*)
association with elevated GRP94 stress protein in breast tumor cells 135-146
estrogen receptor
and reversibility of estrogen resistance in mouse model 93-99
extracellular matrix
induces FAK activation (constitutive in anchorage-independent tumor cells) 173-182

Fas-ligand
from tumor cells and apoptosis of activated lymphocytes — immune evasion 245-253
fibrocystic breast disease
lower cyst fluid TNFα, IL-6, but not IL-1, in high risk group (K+/Na+ > 3) 159-164
focal adhesion kinase (FAK)
constitutively activated in all breast tumor but not normal cells in monolayer 173-182

glucose-regulated proteins (GRP's)
high GRP94 in tumor vs. normal mammary cells, especially with low glucose 135-146
gross cystic disease
lower cyst fluid TNFα, IL-6, but not IL-1, in high risk group (K+/Na+ > 3) 159-164

Ha-*ras* transformation
and down-regulation of vitamin D receptor and response 123-134
HC-11 mouse mammary epithelial cells
vitamin D receptor regulation by growth factors, differentiation, Ha-*ras* transformation 123-134
hematopoietic stem cell support
in high-dose chemotherapy — argument for randomized trials 31-38
hereditary breast cancer
review of BRCA1 and BRCA2 1-10
high-dose chemotherapy
argument for randomized trials 31-38
phase I/II trial of high-dose mitoxantrone — no advantage over standard dose 225-233
hormone dependence
correlation with additionally-glycosylated SHBG variant 101-107
hormone independence
reversibility in mouse tumor model 93-99

IGF binding proteins
regulation by IGF-I and retinoic acid 11-23
immune surveillance
evasion — Fas-ligand from tumor cells and apoptosis of Fas-bearing lymphocytes 245-253
interleukins
lower breast cyst fluid TNFα, IL-6, but not IL-1, in high risk group (K+/Na+ > 3) 159-164

lactogenic hormones
and up-regulation of vitamin D receptor 123-133
lymphocytic infiltrate
Fas-ligand from tumor cells and apoptosis of Fas-bearing lymphocytes 245-253

mammary differentiation
vitamin D receptor regulation by growth factors, differentiation, Ha-*ras* transformation 123-133
mammography
cost-effectiveness analysis of double-reading of mammograms 261-267
screening effect on tumor stage at detection, treatment, and outcome 73-81
MCF-7 human breast cancer cells
loss of tunicamycin stress response 135-146
metalloproteases (MMPs)
inhibitor TIMP-1 is also a growth factor 235-244
metastasis
correlation with reduced telomere DNA content 59-64

metastasis (*continued*)
synergism of c-Myc and Bcl-2 in lymph node progression 39-45
mitoxantrone
phase I/II trial of high-dose — no advantage over standard dose 225-233
phase II trial of mitoxantrone doses with fixed paclitaxel 165-171
molecular chaperones
high GRP94 in tumor vs. normal mammary cells 135-146
mouse mammary tumors
ER, PgR, and reversibility of estrogen resistance 93-99
multistate model
for studying prognostic factors for each transition in breast cancer progression 83-89
Myc oncogene
c-Myc synergizes with Bcl-2 in promoting lymph node metastasis 39-45

older women
decline of upper body function after different breast cancer treatments 25-30

paclitaxel
phase II trial of mitoxantrone doses with fixed paclitaxel 165-171
plasminogen activator inhibitor type 1 (PAI-1)
prognostic value over uPA, cathepsin D, and SPF 147-157
pp125^{fak}
constitutively activated in breast tumor but not normal cells 173-182
predictive factors
angiogenesis, low PgR, and poor survival in node-positive breast cancer with adjuvant anthracycline 205-212
progesterone receptor
and reversibility of estrogen resistance in mouse model 93-99
significant with angiogenesis in node-positive prognosis 205-212
prognostic factors
angiogenesis, low PgR, and poor survival in node-positive breast cancer with anthracycline adjuvant therapy 205-212
multistate model for each transition in tumor progression 83-89
reduced telomere DNA content correlates with genomic instability and metastasis 59-64
tumor blood flow by ultrasonography 65-71
prognostic factors (*continued*)
value of PAI-1 over uPA, cathepsin D, and SPF 147-157
proliferation rate
SPF prognostic significance less than PAI-1 147-157
psychological adjustment to breast cancer
age-related differences in coping and emotional distress 195-203
hampered by cognitive avoidance — cluster analysis 185-194
psychosocial aspects
predictors of quality of life before and after recurrence 47-57

quality of life
and cost issues in deciding on third-line chemotherapy 213-223
before and after recurrence — predictors 47-57

radiation therapy
and decline of upper body function in older women 25-30
with conservative surgery in DCIS — quality of life 109-115
recurrence
effect on quality of life reports 47-57
retinoids
regulation of IGF binding proteins 11-23

S-phase fraction
prognostic significance less than PAI-1 147-157
screening
cost-effectiveness analysis of double-reading of mammograms 261-267
effect on tumor stage at detection, treatment, and outcome 73-81
sex hormone binding globulin (SHBG)
incidence and correlation with hormone dependence in breast neoplasms 101-107
sporadic breast cancer
review of BRCA1 and BRCA2 1-10
stress proteins
high GRP94 in tumor vs. normal mammary cells 135-146
surgery
decline of upper body function after different breast cancer surgical treatments 25-30

tamoxifen
non-significant increased risk of endometrial cancer (4109 patients) 255-260

tamoxifen (*continued*)
randomized trial vs. DES in metastatic breast cancer 117-122
telomere DNA content
correlation with genomic instability and metastasis 59-64
tissue inhibitor of metalloprotease 1 (TIMP-1)
also an autocrine/paracrine growth factor 235-244
tumor immunology
Fas-ligand from tumor cells and apoptosis of Fas-bearing activated lymphocytes 245-253
tumor necrosis factor α
lower breast cyst fluid TNFα, IL-6, but not IL-1, in high risk group (K+/Na+ > 3) 159-164
tumor progression
multistate model for prognostic factors for each transition 83-89
tumor suppressor genes
review of BRCA1 and BRCA2 1-10
tunicamycin
in GRP induction — loss of sensitivity in MCF-7 cells 135-146

ultrasonography
measuring tumor blood flow prognosis 65-71
upper body function
decline after different modes of breast cancer treatment 25-30
urokinase-type plasminogen activator (uPA)
prognostic significance less than PAI-1 147-157

vitamin D receptor
regulation by growth factors, lactogenic hormones, and Ha-*ras* transformation 123-133